

**GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS & FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA
UNSTARRED QUESTION NO. 299
TO BE ANSWERED ON THE 19th NOVEMBER, 2019

Conference in NIPER

299: SHRIMATI RAKSHA NIKHIL KHADSE

Will the Minister of **CHEMICALS AND FERTILIZERS** be pleased to state:

- (a) the details regarding the international conference on Neurological disorders & Therapeutics organized at National Institute of Pharmaceuticals Education & Research (NIPER) recently to explore & encourage approaches to stimulate new ideas for research & treatment in this spectrum, as in the recent scenario, India is the largest exporter of generic drugs globally;
- (b) whether the Government is taking steps to establish world class research & development facilities in the country so as to make the country the topmost drug discovery & innovation hub in the world; and
- (c) if so, the details thereof?

ANSWER

MINISTER IN THE MINISTRY OF CHEMICALS AND FERTILIZERS
(SHRI D. V. SADANANDA GOWDA)

(a) Sir, The International conference on Neurodegenerative Diseases and Therapeutics (ICNDT) was organized by the National Institute of Pharmaceuticals Education & Research (NIPER) Ahmedabad from 24th -26th October 2019 at Gandhinagar, Gujarat. About 32 world renowned national and international scientists delivered plenary and keynote talks in the conference. The international conference brought neuroscientists, clinicians and basic researchers from renowned institutes of the world on the same platform to discuss the problems related to neurodegenerative diseases and its potential therapies. The Conference also opened avenues for the Institutes in the country to establish future research collaboration with world renowned universities. It also opened a window for national and international scientists to work together in collaboration towards innovative research in neuroscience.

(b) & (c) The details are given at **Annexure**.

Annexure referred to in part (c) and (d) of Lok Sabha Unstarred Question No. 299 for reply on 19th November 2019 regarding 'Conference in NIPER' raised by Shrimati Raksha Nikhil Khadse

The details of various steps taken by the Government of India to establish pharmaceutical research and development facilities in the country are as following:

- (i) The Department of Pharmaceuticals has established seven National Institutes of Pharmaceutical Education & Research (NIPERs) at Mohali, Hyderabad, Ahmedabad, Guwahati, Kolkata, Raebareli and Hajipur to promote basic and applied research catering to the needs of pharma industry. These Institutes impart postgraduate and PhD education in various specialization of pharmaceuticals. Further, these NIPERs carryout research in the areas of New Drug Discovery and Drug Development in various therapeutic areas.
- (ii) The Council of Scientific and Industrial Research (CSIR) under the Department of Science & Technology supports drug research through state-of-the-art infrastructure and facilities at its constituent laboratories like CSIR-Central Drug Research Institute (CSIR-CDRI), CSIR-Indian Institute of Chemical Technology (CSIR-IICT), CSIR-Institute of Microbial Technology (CSIR-IMTECH), CSIR-Indian Institute of Toxicology Research, etc. The laboratories are pursuing drugs and pharmaceutical Research and Development activities with an emphasis on affordable healthcare.
- (iii) The Department of Science and Technology (DST), under the Drugs and Pharmaceuticals Research Programme (DPRP), supports projects for creation of facilities where leading academic institutions/national laboratories having scientific expertise can cater to the needs of Pharma Industries. Under this programme, specialized structures like cold rooms, animal house isolation chambers, etc. can be created. Under this programme up to 2018-19, 55 state-of-the-art infrastructure facilities for Pharmaceutical Research and Development have been created indifferent premier institutions and Universities, including Facilities for Bio- availability, Pharmacoinformatics, Regulatory Toxicology, Safety Pharmacology at NIPER, Mohali; Pharmacokinetic & Metabolic Studies, Regulatory Pharmacology & Toxicology, Medium Throughput Screening at CDRI, Lucknow; Transgenic & Gene Knockout Mice, Clinical Research facility to Stem Cell Technologies and regenerative medicine, Biosafety Laboratory at CCMB, Hyderabad and Bioequivalence, Pharmacovigilance, New Chemical Entities development, Animal Facilities for Indian Systems of Medicine in other Universities & Institutions.
- (iv) To strengthen research facilities for drug development, the Indian Council of Medical Research (ICMR) under the Department of Health Research has identified the Product Development Centres at PGIMER-Chandigarh, CDRI-Lucknow, Nizam Institute-Hyderabad, Seth G.S. Medical Collage & KEM Hospital-Mumbai and AIIMS-Delhi. These centres will evaluate potential products

developed by ICMR funded projects in colleges/ICMR centres/centre for advance research. The Centres carry out clinical trials for developing national guidelines/ programs, for new drugs e.g. phytopharmaceuticals.

- (v) The Department of Biotechnology (DBT), towards strengthening the product development for Biopharmaceuticals, has initiated a Mission entitled: Industry-Academia Collaborative Mission for Accelerating Discovery Research to Early Development for Biopharmaceuticals-“Innovate in India (i3) Empowering biotech entrepreneurs & accelerating inclusive innovation”. The National Biopharma Mission approved by the Cabinet at a total cost of US\$ 250 million for five years with 50% funding through World Bank loan is being implemented by Biotechnology Industry Research Assistance Council (BIRAC) - a Public Sector Undertaking of Department of Biotechnology (DBT). The Mission is focusing on development of (i) Vaccines for Pneumococcus, Dengue, HPV and candidates for other diseases of high burden in India (ii) Biosimilars for cancer, diabetics and rheumatoid arthritis and (iii) Medical devices and diagnostics (iv) Process Development Laboratory; Chemistry, Manufacturing, Control Units and CGLP validation facility for Bio therapeutics.
